DEXA
OtherThe appendicular muscle mass measured by DEXA
Other names: Dual Energy X-ray Absorptiometry
NCT Number: NCT02806154
The investigators could hypothesize that age-related changes in body composition parameters play a role in the variable tolerance to chemotherapy in the elderly.
Looking for future studies?
Notify MeHowever none of the studies relating body composition and chemotoxicity included elderly as a specific subpopulation. Furthermore in the majority of studies, body composition analyses are based on the estimation of muscle mass by CT scanner (axial L3 section). This method is to date not validated in the elderly cancer patients. Nevertheless some studies used Dual Energy X-ray Absorptiometry (DEXA), which is considered the gold standard in the assessment of body composition in older adults.
The investigators main hypothesis is that the appendicular muscle mass (I.e. muscle mass of the 4 limbs) operationalized as an index by dividing the muscle mass by squared height following Baumgartners' approach (Baumgartner, 1998) measured by DEXA (total of muscle mass of 4 limbs / height ²) represents a predictive factor of chemotoxicity in the elderly.
The finding that body composition is associated with poor tolerance of chemotherapy could lead to consider these parameters in the treatment decision of the elderly cancer patients and improve the current decision-making algorithms when treating older adults.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The appendicular muscle mass measured by DEXA
Other names: Dual Energy X-ray Absorptiometry
Time frame: Up to 12 months
Toxicity event defined by : first occurrence of grade 4 hematologic or grade 3-4 non hematologic toxicity as defined by the National Cancer Institute-Common Toxicity Criteria (NCI-CTC version 4) and/or disruption of chemotherapy because of inacceptable toxicity.
Time frame: Up to 12 months
defined as a loss of ≥ 0.5 point in Activities of Daily Living Scale.
Time frame: Up to 12 months
defined as a loss ≥ 1 point in the Short Physical Performance Battery
Time frame: Up to 12 months
defined as a loss ≥ 10 points in the EORTC quality of life questionnaire (QLQ) QLQ-C30 questionnaire
Time frame: Up to 12 months
defined by a death occuring during the 3 first months from the initiation of the treatment
University Hospital, Toulouse
Other
Acronym: FRACTION
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01445483
Brain Diseases, Brain Metastasis
Bethesda, Maryland, United States
View Trial DetailsNCT01498276
Cancer, Cardiovascular Diseases
Washington D.C., District of Columbia, United States
View Trial DetailsNCT05203614
Cancer, Neoplasms
Houston, Texas, United States
View Trial DetailsNCT04455698
Cancer, Neoplasms
Chicago, Illinois, United States
View Trial Details